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Abstract
: We have recently demonstrated that oral intake of glycine propionyl-L-carnitine (GPLC) increases
plasma nitrate/nitrite (NOx), a surrogate measure of nitric oxide production. However, these
findings were observed at rest, and in previously sedentary subjects.
Purpose: In the present study, we sought to determine the impact of oral GPLC on plasma NOx
at rest and in response to a period of reactive hyperemia in resistance trained men.
Methods: Using a double blind, crossover design, 15 healthy men (24 ± 4 years) were assigned to
GPLC (3 g/d PLC + 1044 mg glycine) and a placebo in random order, for a four-week period, with
a two-week washout between condition assignment. Blood samples were taken from subjects at
rest and at 0, 3, and 10 minutes following an ischemia-reperfusion protocol (six minutes of upper
arm cuff occlusion at 200 mmHg followed by rapid reperfusion with cuff removal). Blood samples
were taken from a forearm vein from the same arm used for the protocol and analyzed for total
nitrate/nitrite. Data are presented as mean ± SEM.
Results: A condition main effect (p = 0.0008) was noted for NOx, with higher values in subjects
when using GPLC (45.6 ± 2.8 μmol·L-1) compared to placebo (34.9 ± 1.2 μmol·L-1). No time main
effect was noted (p = 0.7099), although values increased approximately 12% from rest (37.7 ± 2.7
μmol·L-1) to a peak at 10 minutes post protocol (42.3 ± 3.3 μmol·L-1). The interaction effect was
not significant (p = 0.8809), although paired time contrasts revealed higher values for GPLC
compared to placebo at 3 (48.2 ± 6.7 vs. 34.9 ± 2.4 μmol·L-1; p = 0.033) and 10 (48.8 ± 5.9 vs. 35.7
± 2.1 μmol·L-1; p = 0.036) minutes post protocol, with non-statistically significant differences noted
at rest (41.8 ± 4.5 vs. 33.6 ± 2.5 μmol·L-1; p = 0.189) and at 0 minutes (43.6 ± 5.1 vs. 35.4 ± 2.7
μmol·L-1; p = 0.187) post protocol. An analysis by subject (collapsed across time) indicated that 11
of the 15 subjects experienced an increase in NOx with GPLC treatment.
Conclusion: These findings indicate that short-term oral GPLC supplementation can increase
NOx in resistance trained men. However, as with many dietary supplements, there exist both
"responders" and "non-responders" to treatment. Future work may focus on the mechanisms for
the discrepancy in response to GPLC supplementation for purposes of NOx elevation.
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Introduction
Nitric oxide (NO•) is an important signaling molecule,
promoting vasodilation by acting on vascular smooth
muscle [1]. In addition, NO￿ has been linked to other
physiological functions such as inhibition of platelet
aggregation and platelet adhesion [2]. In these ways, NO￿
mediates increased blood flow at rest [3-5] and during
exercise [4,6,7], which may have implications for those
with chronic ischemic disease as well as for athletes inter-
ested in enhancing blood flow to working skeletal muscle
(e.g., endurance athletes, bodybuilders).
Nitric oxide is synthesized from L-arginine by the
endothelium in the vascular system [2] and has been
reported to increase in response to acute exercise [8-13].
This is true for dynamic [4], as well as for isometric [7]
exercise, in which reperfusion is present following cessa-
tion of the contraction. Moreover, chronic exercise train-
ing has been reported to result in an increase in plasma
nitrate/nitrite (NOx) levels [14-16], a surrogate marker of
NO￿.
Aside from exercise, pharmaceutical agents have been
used with success to induce NO￿  biosynthesis, in an
attempt to promote vasodilation (for review please see
[17]). Treatments have sometimes included high dosages
of L-arginine, often provided via intravenous injection.
This has led to the development of several nutritional sup-
plements, often containing small amounts of L-arginine,
which are purported to have "drug-like" action, ultimately
leading to increased NO￿. While the fitness industry is
inundated with advertisements for such products, the sci-
entific data are scant. We have recently demonstrated an
increase in plasma NOx in healthy sedentary subjects fol-
lowing oral treatment with a novel carnitine agent, glycine
propionyl-L-carnitine (GPLC; [18]). This finding extends
recent work of Lofreddo et al. [19] who reported an
increase in blood NOx in response to 6 grams per day of
PLC given via IV infusion to patients with peripheral arte-
rial disease. Other reports suggest vasodilatation actions
with PLC [20], in addition to glycine [21] treatment inde-
pendently. However, our initial findings using oral GPLC
were observed at rest, and in previously sedentary sub-
jects, individuals who quite possibly have lower resting
NOx levels compared to well-trained subjects; hence, may
have a greater potential for responding to GPLC treat-
ment. To our knowledge, no studies have been done to
evaluate the efficacy of nutritional supplements to
increase NOx levels in a sample of potential users (e.g.,
resistance trained athletes). Therefore, in the present
study, our purpose was to determine the impact of oral
GPLC on plasma NOx at rest and in response to a period
of reactive hyperemia in resistance trained men. Using a
double blind, randomized, crossover design, we hypothe-
sized that plasma NOx would be higher with GPLC treat-
ment compared to placebo, at rest and in response to the
ischemia-reperfusion protocol.
Methods
Subjects
Fifteen healthy, resistance trained men participated in this
investigation. Subjects completed a medical history, diet
and supplementation history, and physical activity ques-
tionnaire to determine eligibility. No subject was a
smoker or used anti-inflammatory drugs or antioxidant
supplements before (for a minimum of six months) or
during the study period. Subjects were young (24 ± 4 yrs;
mean ± SD), and of average height (177 ± 5 cm), weight
(83 ± 4 kg), and body fat percentage (14 ± 5 %). Subjects
were considered to be well-trained and performed resist-
ance exercise for 5 ± 2 hrs per week for 8 ± 5 yrs. They were
instructed not to deviate from their current training regi-
men during the course of the study with the exception of
refraining from exercise for the 48 hours prior to each test-
ing day. All experimental procedures were performed in
accordance with the Helsinki Declaration. The University
of Memphis Human Subjects Committee approved all
experimental procedures. All subjects provided both ver-
bal and written consent prior to participating in this
study.
Conditions
Subjects were randomly assigned in double-blind manner
using a cross-over design to GPLC and a placebo. Each
intake period consisted of four weeks, with a two-week
washout period between condition assignments. Subjects
were instructed to ingest a total of six capsules per day of
GPLC or placebo (at two separate times – morning and
evening). Based on recent evidence indicating that carni-
tine uptake is enhanced with carbohydrate feeding
[22,23], subjects were instructed to take capsules along
with a carbohydrate rich meal. GPLC is a USP grade nutri-
tional supplement as of March 2006, consisting of a
molecular bonded form of propionyl-L-carnitine (PLC)
and the amino acid glycine (GlycoCarn™, Sigma-tau
HealthScience S.p.A, Rome, Italy). In the total 4.5 g/d dos-
age of GPLC, the actual PLC content was equal to 3 g and
the glycine content was equal to 1044 mg (the remainder
of the capsule consisted primarily of cellulose). The short
term (8–9 week) safety of GPLC supplementation at the
dosage provided (4.5 g/d) was established in our initial
work [18], where we noted no adverse changes in subjects'
complete blood count or blood chemistry panel data.
Capsules were manufactured by Jarrow Formulas (Los
Angeles, CA), were identical in appearance, and were pro-
vided to subjects in unlabeled bottles every two weeks.
Compliance to intake was determined based on capsule
counts upon bottle return.Journal of the International Society of Sports Nutrition 2007, 4:22 http://www.jissn.com/content/4/1/22
Page 3 of 6
(page number not for citation purposes)
Ischemia reperfusion protocol
Following each four-week period of either GPLC or pla-
cebo intake, subjects underwent a protocol involving five
minutes of upper arm cuff occlusion in conjunction with
submaximal isometric handgrip dynamometry to induce
ischemia. The tests were conducted on day 29, following
the four-week treatment period. The time of testing was
matched for placebo and GPLC conditions for all subjects,
and all testing was done between 0600–0900 hours. All
subjects reported to the lab for testing, on both days, in a
10-hour fasted state. No food was allowed until after the
10-min post protocol blood draw. A standard blood pres-
sure cuff was applied to the dominant upper arm and
inflated to 200 mmHg. This is a common procedure used
in the study of brachial artery blood flow in response to
various stimuli, which results in enhanced blood flow and
artery dilation during the reperfusion period, mediated by
NO￿ [24-27]. Hence, we used this protocol to study the
plasma NOx response. At the end of the five minute
period, subjects performed an isometric contraction using
a handgrip dynamometer at 50% of their maximal prede-
termined capacity, for one minute. Therefore, the total
duration of cuff occlusion was six minutes. At the end of
the six minute period, the pressure in the cuff was imme-
diately removed to allow for rapid reperfusion (reactive
hyperemia). Blood samples were collected before, imme-
diately post (0), 3 min post, and 10 min post protocol, as
described below.
Blood collection and biochemistry
Venous blood samples (~7 mL) were taken from subjects
via needle and EDTA containing vacutainer by a trained
phlebotomist. Following collection, blood samples were
placed on ice and immediately centrifuged at 1500 × g at
4°C for 15 min. Plasma was then removed and immedi-
ately stored at -80°C until assayed for nitrate/nitrite
(NOx). Nitrate/nitrite was analyzed using commercially
available assay kits (Caymen Chemical, Ann Arbor, MI).
Following conversion of nitrate to nitrite using nitrate
reductase, Greiss reagent was added to the sample, which
converts nitrite into a deep purple azo compound. The
absorbance of this azo chromophore was then detected
photometrically at 540 nm using a BioTek Instruments
Powerwave 340 microplate reader (Winooski, Vermont),
and unknown sample values were determined using a
nitrite standard curve, via software (BioTek Gen5™).
Assays were performed in duplicate and the coefficient of
variation was 5.1%.
Dietary records
Subjects were instructed to maintain their normal diet
during the study period and to complete food records to
allow for nutrient intake assessment for the seven days
prior to each testing session. Subjects were given specific
instructions regarding the recording of portion sizes and
quantities, in addition to viewing food models in order to
enhance precision. Diet records were analyzed for total
calories, protein, carbohydrate, and fat (Food Processor
SQL, version 9.9, ESHA Research, Salem, OR).
Statistical analysis
Plasma NOx data were analyzed using a 2 (condition) × 4
(time) repeated measures analysis of variance (ANOVA).
Single degree of freedom contrasts were used to determine
condition differences at each time. Such a priori contrasts
do not require adjustment of the type I error rate. Dietary
data were analyzed using a one way ANOVA. These data
are presented as mean ± standard error of the mean. Sub-
ject descriptive characteristics are presented as mean ±
standard deviation. All analyses were performed using
JMP statistical software (version 4.0.3, SAS Institute, Cary,
NC). Statistical significance was set at P ≤ 0.05.
Results
Of the 16 subjects who started the study, only data from
15 subjects were included in the analysis. One subject
failed to return to the lab for the second testing session;
therefore, data for this subject were excluded. Compliance
to GPLC and placebo intake was ≥ 97% for both condi-
tions based on capsule counting upon return of bottles.
Subjects indicated their compliance to our recommenda-
tion of maintenance of their specific exercise regimen dur-
ing the course of the study period. The mean daily intake
of kilocalories (2750 ± 195 vs. 2801 ± 217; p = 0.86), pro-
tein grams (155 ± 14 vs. 157 ± 15; p = 0.91), carbohydrate
grams (330 ± 23 vs. 340 ± 34; p = 0.76), and fat grams (87
± 9 vs. 81 ± 7; p = 0.60) during the week prior to GPLC and
placebo conditions, respectively, did not differ. Analyses
of diet records indicated that no subject regularly con-
sumed nitrate- (e.g., spinach, cabbage, beets, radishes) or
nitrite-rich foods during the diet reporting periods; there-
fore, we do not believe that dietary intake influenced the
plasma NOx values.
A condition main effect (p = 0.0008) was noted for NOx,
with higher values in subjects when using GPLC (45.6 ±
2.8 μmol·L-1) compared to placebo (34.9 ± 1.2 μmol·L-
1). No time main effect was noted for NOx (p = 0.7099),
although values increased approximately 12% from rest
to a peak at 10 minutes post protocol. The interaction
effect for NOx was not significant (p = 0.8809), although
paired time contrasts revealed higher values for GPLC
compared to placebo at 3 (p = 0.033) and 10 (p = 0.036)
minutes post protocol. The interaction data for NOx are
presented in Figure 1. An analysis by subject (collapsed
across time) indicated that 11 of the 15 subjects experi-
enced an increase in NOx with GPLC treatment (Figure 2).Journal of the International Society of Sports Nutrition 2007, 4:22 http://www.jissn.com/content/4/1/22
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Discussion
We report for the first time that a nutritional supplement,
in the form of oral GPLC, can increase plasma NOx in
resistance trained men. These findings may have implica-
tions for enhanced blood flow to active skeletal muscle
during exercise. This may be important for endurance ath-
letes, for whom increased blood flow may aid exercise per-
formance [15,28], as well as for bodybuilders, for whom
increased blood flow may lead to greater delivery of sub-
strates (e.g., amino acids) during recovery, which may
increase protein synthesis [29].
Although we noted no time main effect or interaction
effect of NOx (Figure 1), values were generally higher at all
times following the protocol, with a peak increase from
rest at 10 minutes post protocol. Furthermore, although
no interaction effect was noted, values were statistically
higher with the GPLC treatment compared to placebo at 3
and 10 minutes post protocol, with non-statistically
higher values noted at rest and at 0 minutes post protocol.
Therefore, while resting NOx levels may not be increased
significantly with GPLC treatment in resistance trained
men, NOx in response to an acute physical stimulus
appears higher with GPLC treatment compared to pla-
cebo. For example, the increase from rest with GPLC was
16% and 17% at 3 and 10 minutes post protocol, respec-
tively. Whereas, the increase from rest with placebo was
only 4% and 6% at 3 and 10 minutes post protocol,
respectively (Figure 1). Although these findings are inter-
esting, future work should include flow mediated dilation
studies as a compliment to the plasma NOx measure-
ment, in order to investigate bloodflow specific changes
due to GPLC treatment. This would provide insight into
the physiological relevance of the NOx increase.
Despite our findings that the majority of subjects
responded to GPLC treatment (11 of 15; Figure 2), there
were those individuals who were "non-responders". This
is common with nutritional supplements, and with
regards to dietary carnitine supplementation, may be
related to carbohydrate intake. That is, based on the recent
findings of Stephens and coworkers [22,23], carbohydrate
rich feedings, which induce a state of hyperinsulinemia,
appear to improve carnitine transport into skeletal mus-
cle. Hence, subjects with a low carbohydrate intake, in
particular as related to the actual time of carnitine inges-
tion, may experience less than optimal uptake into tissue.
This may also be true as related to uptake into endothelial
cells. If this were the case, it is possible that the effects of
GPLC on NOx would be minimized. However, we ana-
lyzed the mean daily carbohydrate intake of all subjects
and noted no difference between the carbohydrate intake
of "responders" (342 ± 27 g) and "non-responders (316 ±
31 g). Moreover, we noted no correlation between carbo-
hydrate intake and NOx levels (p = 0.27). Therefore, other
mechanisms must be involved related to these subjects'
inability to respond to GPLC treatment. Future study is
needed to explore the potential mechanisms associated
with this finding. In addition, the specific mechanisms
responsible for the increase in plasma NOx with GPLC
supplementation remain to be elucidated. That is, in vitro
data indicate that maintenance of NO￿ with PLC treat-
ment may be associated with decreased NADPH oxidase
activation [30], an enzyme which subsequently leads to
superoxide radical generation [31] and decreased NO￿
bioavailability. Moreover, recent work indicates that PLC
augments endothelial nitric oxide synthase (eNOS) [32],
the major enzyme responsible for NO￿  production.
Clearly, these findings provide some mechanistic evi-
dence to support our data; however more work is needed
to more fully understand the mechanisms associated with
the increase in plasma NOx (perhaps investigation of sec-
ond messenger systems such as cGMP) with GPLC supple-
mentation in human subjects.
Conclusion
In summary, our findings indicate that short-term oral
GPLC supplementation can increase NOx in resistance
trained men. However, there exist both "responders" and
"non-responders" to treatment. Findings from this study
may have health implications for those with ischemic
Plasma nitrate/nitrite before and after an ischemia-reper- fusion protocol in 15 resistance trained men supplemented  with GPLC and placebo in a cross-over design Figure 1
Plasma nitrate/nitrite before and after an ischemia-
reperfusion protocol in 15 resistance trained men 
supplemented with GPLC and placebo in a cross-
over design. Note: Condition main effect (p = 0.0008); No 
time main effect (p = 0.7099) or interaction effect (p = 
0.8809); paired time contrasts at 3 (p = 0.033) and 10 (p = 
0.036) minutes post protocol; rest (p = 0.189) and 0 (p = 
0.187) minutes post protocol; % change from rest presented 
for each time post protocol. Values are mean ± SEM.
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conditions such as peripheral vascular disease and
ischemic heart disease, as increased NOx may allow for
enhanced blood flow, in particular during times of physi-
cal stress. Moreover, these findings may relate specifically
to athletes who seek enhanced blood flow during periods
of strenuous exercise, as such a change may be associated
with improved physical performance during training and
optimal post exercise recovery. Future study is needed to
determine what, if any, physiologic benefit is associated
with the observed increase in plasma NOx with GPLC
supplementation.
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